Schöttle D, et al. - Researchers undertook this non-interventional study, prospective, multicenter 6-month study investigating the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (AOM) under real-life conditions in a naturalistic population. They assessed 242 predominantly symptomatically stable patients (mean age 43.1 ± 15.1 years, 55% male) who transitioned to AOM after 9.7 (± 22.3) months of oral treatment. Evaluation of functionality (Global Assessment of Functioning), patient’s wellbeing (WHO-5 Well-Being Index, WHO-5), and both patient’s and clinician’s assessment of efficacy and tolerability of AOM led to the findings that initiation of AOM treatment has a significant positive effect on the functioning and wellbeing in predominantly stable patients with schizophrenia. The effect was even more proclaimed in patients aged ≤ 35 years, thereby strengthening previous randomized controlled findings under routine conditions in clinical practice.